Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CA67059R1091
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG002CV5Z46
NRX
NurExone Biologic Inc.
GICS: - · SECTOR: EQTY · SUB-SECTOR: -
NAME
NurExone Biologic Inc.
ISIN
CA67059R1091
TICKER
NRX
MIC
XTSX
REUTERS
NRX.V
BLOOMBERG
NRX CN
Fri, 09.08.2024       NurExone
CA67059R1091

NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.07.2024       NurExone
CA67059R1091

Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.06.2024       NurExone
CA67059R1091

Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.06.2024       NurExone
CA67059R1091

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice Pre...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.06.2024       NurExone
CA67059R1091

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.05.2024       NurExone
CA67059R1091

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.05.2024       NurExone
CA67059R1091

NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.07.2023       NurExone
CA67059R1091

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons....
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.05.2023       NurExone
CA67059R1091

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Resea...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.05.2023       NurExone
CA67059R1091

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive st...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 12.01.2023       NurExone
CA67059R1091

The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System diseaseHaifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy"...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.12.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to provide the following shareholder letter from Nur...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.12.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it completed its securities for...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.12.2022       NurExone
CA67059R1091

Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapiesNurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error.Calgary, Alberta--(Newsfile Corp. - December 1, 2022) -...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.11.2022       NurExone
CA67059R1091

Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapiesCalgary, Alberta--(Newsfile Corp. - November 30, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoThera...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.11.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amoun...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.11.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter e...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.11.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.11.2022       NurExone
CA67059R1091

The U.S. Food and Drug Administration (FDA) informed NurExone that it is at the appropriate stage of its product development for a pre-Investigational New Drug (pre-IND) meetingA pre-IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into the U.S. market.Calgary, Alberta--(Newsfile Corp. - November...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.10.2022       NurExone
CA67059R1091

Results indicate that the proprietary production process boosts exosome productivity, improving cost-efficiencyCalgary, Alberta--(Newsfile Corp. - October 26, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients wit...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 20.10.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - October 20, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company will be participating in the upcoming 2022 Bio-Europ...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.10.2022       NurExone
CA67059R1091

Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExon...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.10.2022       NurExone
CA67059R1091

Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExon...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.10.2022       NurExone
CA67059R1091

Results show a significant increase in effectiveness of NurExone's therapeutic compounds in inhibition of PTEN expressionCalgary, Alberta--(Newsfile Corp. - October 4, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for pat...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.10.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - October 3, 2022) - Further to our news release of September 1, 2022, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.09.2022       NurExone
CA67059R1091

Calgary, Alberta, Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is pleased to announce that the Company has entered into a letter of...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.09.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - September 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.08.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - August 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients suffering from traumatic spinal cord injuries, released a business update and reported financial results for the q...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.08.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, released excerpts from a letter uploaded to Sedar today from Mr. Jay Richardson, For...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.07.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - July 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) ("NurExone" or the "Company"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, is pleased to announce that it will showcase a poster pres...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.07.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - July 19, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, announced the si...
Read more
NurExone
Technical Analysis Termsheets Terminal
Permalink